Proud Amneal Offers Preview Of Q1 Growth
Preliminary Figures Show Sales Up 12%, Adjusted EBITDA Up 18% In First Quarter Of 2023
Ahead of revealing its full first-quarter results, Amneal has released limited preliminary details of its financials for the first three months of 2023, pointing to double-digit sales and profit growth in Q1.
You may also be interested in...
Stressing the need for vertical integration to be a successful biosimilars developer in the long run, Amneal co-CEO Chirag Patel has set out the firm’s future strategy in the area – including aiming to be quicker to market with future launches – as Amneal proves itself against rival biosimilars players in the US market.
Amid upheaval for leading industry players Sandoz, Teva and Viatris, Amneal sees room to grow both in its home market and internationally, according to co-CEO Chirag Patel.
Following Amneal’s first biosimilar launch last month, the company has made it two with the introduction of its Releuko version of filgrastim in the US. It plans to complete the trinity with its Fylnetra pegfilgrastim biosimilar early next year.